Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease

Gut

Volumn 65, Issue 5, 2016, Pages 830-839

  Llopis, M ^a,b,c   Cassard, A M ^a,b   Wrzosek, L ^a,b   Boschat, L ^c   Bruneau, A ^c   Ferrere, G ^a,b   Puchois, V ^a,b   Martin, J C ^a,d   Lepage, P ^c   Le Roy, T ^c   Lefevre L ^e   Langelier, B ^c   Cailleux, F ^a,b   Gonzalez Castro A M ^f   Rabot, S ^c   Gaudin, F ^g   Agostini, H ^h   Prevot S ^b,i   Berrebi, D ^a,j   Ciocan, D ^a,b,i   Jousse, C ^k   Naveau, S ^a,b,i   Gerard P ^c   Perlemuter, G ^a,b,i   more..

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UMR1319 MICALIS   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e UMR1313 GÉNÉTIQUE ANIMALE ET BIOLOGIE INTÉGRATIVE   (France)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g IPSIT   (France)

^h BICÊTRE HOSPITAL   (France)

ⁱ HÔPITAL ANTOINE BÉCLÈRE   (France)

^j HÔPITAL ROBERT DEBRÉ   (France)

^k UNIVERSITÉ CLERMONT AUVERGNE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN;

ADULT; ALCOHOL LIVER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DYSBIOSIS; FAECALIBACTERIUM; FEMALE; INTESTINE FLORA; INTRAABDOMINAL FAT; LIVER NECROSIS; LYMPHOCYTE SUBPOPULATION; MESENTERY LYMPH NODE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; POPULATION ABUNDANCE; PRIORITY JOURNAL; SPECIES COMPOSITION; ANIMAL; C57BL MOUSE; COMPLICATION; HUMAN; MICROBIOLOGY;

ANIMALS; DISEASE SUSCEPTIBILITY; DYSBIOSIS; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; LIVER DISEASES, ALCOHOLIC; MICE; MICE, INBRED C57BL;

EID: 84954287816     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-310585     Document Type: Article

References (34)

1. Teli MR, Day CP, James O. F. W, Burt AD, et al. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995;346:987-90.
2. Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014;60:940-7.
3. Parlesak A, Schäfer C, Schütz T, et al. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol 2000;32:742-7.
4. Ferrier L, Bérard F, Debrauwer L, et al. Impairment of the intestinal barrier by ethanol involves enteric microflora and mast cell activation in rodents. Am J Pathol 2006;168:1148-54.
5. Szabo G, Bala S, Petrasek J, et al. Gut-liver axis and sensing microbes. Dig Dis 2010;28:737-44.
6. Chen P, Torralba M, Tan J, et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology 2015;148:203-14.e16.
7. Bode JC, Bode C, Heidelbach R, et al. Jejunal microflora in patients with chronic alcohol abuse. Hepatogastroenterology 1984;31:30-4.
8. Yan AW, Fouts DE, Brandl J, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011;53:96-105.
9. Leclercq S, Matamoros S, Cani PD, et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci USA 2014;111:E4485-93.
10. Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014;513:59-64.
11. International Group. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet 1981;1:707-11.
12. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008;105:16731-6.
13. Brandon-Warner E, Schrum LW, Schmidt CM, et al. Rodent models of alcoholic liver disease: of mice and men. Alcohol 2012;46:715-25.
14. Bigorgne AE, Bouchet-Delbos L, Naveau S, et al. Obesity-induced lymphocyte hyperresponsiveness to chemokines: a new mechanism of Fatty liver inflammation in obese mice. Gastroenterology 2008;134:1459-69.
15. Naveau S, Cassard-Doulcier AM, Njiké-Nakseu M, et al. Harmful effect of adipose tissue on liver lesions in patients with alcoholic liver disease. J Hepatol 2010;52:895-902.
16. Devkota S, Wang Y, Musch MW, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/-mice. Nature 2012;487:104-8.
17. Wei B, Dalwadi H, Gordon LK, et al. Molecular cloning of a Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory bowel disease marker antibody. Infect Immun 2001;69:6044-54.
18. Carvalho FA, Koren O, Goodrich JK, et al. Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice. Cell Host Microbe 2012;12:139-52.
19. Gérard P. Metabolism of cholesterol and bile acids by the gut microbiota. Pathogens 2014;3:14-24.
20. Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 1994;330:1342-7.
21. Bertola A, Mathews S, Ki SH, et al. Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat Protoc 2013;8:627-37.
22. Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology 2015;148:30-6.
23. Le Roy T, Llopis M, Lepage P, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013;62:1787-94.
24. Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013;341:1241214.
25. Tuovinen E, Keto J, Nikkilä J, et al. Cytokine response of human mononuclear cells induced by intestinal Clostridium species. Anaerobe 2013;19:70-6.
26. Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013;110:9066-71.
27. Shan M, Gentile M, Yeiser JR, et al. Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science 2013;342:447-53.
28. Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature 2012;489:220-30.
29. Xie G, Zhong W, Li H, et al. Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption. FASEB J 2013;27:3583-93.
30. Sipka S, Bruckner G. The immunomodulatory role of bile acids. Int Arch Allergy Immunol 2014;165:1-8.
31. Langhi C, Pedraz-Cuesta E, Haro D, et al. Regulation of human class I alcohol dehydrogenases by bile acids. J Lipid Res 2013;54:2475-84.
32. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002;36:525-31.
33. Kakiyama G, Pandak WM, Gillevet PM, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013;58:949-55.
34. Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009;58:1091-103.